Revance Therapeutics Inc’s filing revealed that its CMO & Global Therapeutics Lead Hollander David unloaded Company’s shares for reported $16296.0 on Nov 18 ’24. In the deal valued at $4.17 per share,3,908 shares were sold. As a result of this transaction, Hollander David now holds 104,945 shares worth roughly $0.36 million.
Then, Jordan Erica sold 2,392 shares, generating $9,096 in total proceeds. Upon selling the shares at $3.80, the Chief Commercial Officer now owns 114,864 shares.
Before that, Sjuts Dustin S sold 9,211 shares. Revance Therapeutics Inc shares valued at $46,446 were divested by the President at a price of $5.04 per share. As a result of the transaction, Sjuts Dustin S now holds 167,550 shares, worth roughly $0.57 million.
Mizuho downgraded its Revance Therapeutics Inc [RVNC] rating to a Neutral from a a Buy in a research note published on January 29, 2024; the price target was decreased to $9 from $16. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in early January from “a Buy” to “a Neutral”. Exane BNP Paribas also remained covering RVNC and has increased its forecast on August 16, 2023 with a “Neutral” recommendation from previously “an Underperform” rating. Morgan Stanley started covering the stock on October 11, 2022. It rated RVNC as “an Equal-weight”.
Price Performance Review of RVNC
On Tuesday, Revance Therapeutics Inc [NASDAQ:RVNC] saw its stock fall -1.73% to $3.41. Over the last five days, the stock has gained 11.44%. Revance Therapeutics Inc shares have risen nearly 12.17% since the year began. Nevertheless, the stocks have fallen -59.16% over the past one year. While a 52-week high of $7.59 was reached on 01/06/25, a 52-week low of $2.30 was recorded on 01/02/25. SMA at 50 days reached $3.95, while 200 days put it at $4.25.
Levels Of Support And Resistance For RVNC Stock
The 24-hour chart illustrates a support level at 3.36, which if violated will result in even more drops to 3.30. On the upside, there is a resistance level at 3.49. A further resistance level may holdings at 3.56. The Relative Strength Index (RSI) on the 14-day chart is 50.68, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 34.48%. Stochastics %K at 72.13% indicates the stock is a holding.
How much short interest is there in Revance Therapeutics Inc?
A steep rise in short interest was recorded in Revance Therapeutics Inc stocks on 2024-12-13, dropping by -2.44 million shares to a total of 9.77 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 12.21 million shares. There was a decline of -24.93%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 22, 2022 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.
